About ParaGen Technologies
ParaGen Technologies is a Healthcare company based in Columbus (United States) founded in 2016 by Flavio Lobato. Tissue engineering technologies are developed with synthetic nanofiber scaffolds. It operates in the Healthcare and Chemicals & Materials sectors. ParaGen Technologies has raised $11.64 million across 4 funding rounds from investors including Ikove Capital Partners. The company has 1 employees. Its chief executive, as recorded, is Ross Kayuha. ParaGen Technologies offers products and services including Nanofiber Scaffolds, RenovoDerm, Atreon Orthopedics, Vascular Genesis, and Tarian Medical. Its focus areas include High Tech, Advanced Materials, Biomaterials and Biomimetics. Its competitors include Amyris, AskBio and Ginkgo Bioworks; 3 of its 3 listed competitors have raised funding.
Company details
ParaGen Technologies was founded in 2016 in Columbus, United States, focusing on the tissue engineering sector. Synthetic nanofiber scaffolds are created by the company to replicate the extracellular matrix, supporting healing processes. Applications include wound care, orthopedics, vascular treatments, and hernia repair, with operations centered on advancing medical biomaterials for regenerative purposes.
- Headquarters Columbus, United States
- Employees 1
- Founders Flavio Lobato
- SectorsHealthcareChemicals & Materials
- Email••••••••
- Phone•••• ••••
- Website paragentechnologies.com
- Social LinkedIn X Instagram
- Legal Name Paragen Technologies
- Total Equity Funding$11.64M (USD)
in 4 rounds
- Latest Funding Round$4.45M (USD), Series A
Nov 2021
- Investors
- Employee Count1
Products & Services of ParaGen Technologies
ParaGen Technologies offers a comprehensive portfolio of products and services, including Nanofiber Scaffolds, RenovoDerm, Atreon Orthopedics, Vascular Genesis, and Tarian Medical.
Scaffolds that mimic body structures to promote tissue healing and regeneration
Product for wound healing using nanofiber technology
Device for orthopedic repair with nanofiber scaffolds
Product for vascular regeneration via nanofiber technology
Device for hernia repair using synthetic scaffolds
Funding Insights of ParaGen Technologies
ParaGen Technologies has successfully raised a total of $11.64M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.45 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.64M
- Total Rounds 4
- Last Round Series A — $4.45M
- First Round $4.1M
(Dec 2017)
- Investors Count 1
All 4 funding rounds of ParaGen Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $4.45M | Series A | – | – | – |
| Apr 2019 | $3.09M | Seed | – | – | – |
| Nov 2018 | $3M | Debt – Conventional | – | – | – |
| Dec 2017 | $4.1M | Seed | – | Ikove Capital Partners | – |
1 investors in total: 1 institutional.
Investors in ParaGen Technologies
ParaGen Technologies has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Ikove Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| ikovecapital.com |
Investor details for ParaGen Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ParaGen Technologies
12 people are tracked at ParaGen Technologies (8 in leadership, 3 in board & advisors, 1 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Flavio Lobato | Co-Founder | Leadership |
Ross Kayuha | CEO | Leadership |
Jed Johnson | CTO | Leadership |
Ronald Bracken | COO | Leadership |
Krishna Mannava | Medical Director | Leadership |
Brian Cohen | Medical Director | Leadership |
Anthony Romeo | Medical Director | Leadership |
Wilbur Sever | Medical Director | Leadership |
Rodolfo Bellesi | Board Member | Board & advisors |
Robert Lee | Board Member | Board & advisors |
John D'Orazio | Board Member | Board & advisors |
Kevin Nelson | Process Development Engineer | Team |
Complete people profiles for ParaGen Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ParaGen Technologies
3 dated milestones of ParaGen Technologies across 5 years, from founding to its latest funding, stage changes and deals.
- Founded ParaGen Technologies is founded.
- Funding First funding round of $4.1M.
- Funding Latest funding round, Series A, of $4.4M.
Competitors of ParaGen Technologies
ParaGen Technologies has 3 listed competitors in our database, 3 of them funded. They include Amyris, AskBio and Ginkgo Bioworks.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. | ||
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. |
Detailed competitors of ParaGen Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as ParaGen Technologies (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Paragen Technologies
Complete news archive for ParaGen Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ParaGen Technologies
ParaGen Technologies was founded in 2016 and raised its 1st funding round 1 year after it was founded.
ParaGen Technologies is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Ross Kayuha is the CEO of ParaGen Technologies, as recorded in our data.
ParaGen Technologies is a funded company, having raised a total of $11.64M across 4 funding rounds to date. The company's 1st funding round was a Seed of $4.1M, raised on Dec 2017.
ParaGen Technologies has 1 employees.
ParaGen Technologies was founded in 2016 in Columbus, United States, focusing on the tissue engineering sector. Synthetic nanofiber scaffolds are created by the company to replicate the extracellular matrix, supporting healing processes. Applications include wound care, orthopedics, vascular treatments, and hernia repair, with operations centered on advancing medical biomaterials for regenerative purposes.
ParaGen Technologies's top competitors include Amyris, AskBio and Ginkgo Bioworks.
ParaGen Technologies offers Nanofiber Scaffolds, RenovoDerm, Atreon Orthopedics, Vascular Genesis, and Tarian Medical.
ParaGen Technologies has 1 investor. Key investors include Ikove Capital Partners.
ParaGen Technologies operates through Paragen Technologies.